• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Mucoadhesive gel containing immunotherapeutic nanoparticulate satranidazole for treatment of periodontitis: development and its clinical implications
【24h】

Mucoadhesive gel containing immunotherapeutic nanoparticulate satranidazole for treatment of periodontitis: development and its clinical implications

机译：含免疫治疗性纳米颗粒硝呋喃唑的粘膜粘附凝胶治疗牙周炎的发展及其临床意义

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to alleviate shortcomings in periodontal treatment by utilizing a mucoadhesive gel containing immunotherapeutic ganglioside coated polymeric nanoparticles (G-PNP) bearing satranidazole (SZ). Nanoprecipitation was used to fabricate SZ loaded G-PNP. In our previous deliberations aqueous dispersibility of conventional SZ had raised dose consistency issues. Usage of G-PNP allayed those fears as DSC and XRD data showed that SZ was rendered amorphous (more water dispersible than crystalline SZ) when captured in a polymeric matrix of nanoparticles. G-PNP were added to sodium carboxy methyl cellulose (SCMC 30 NP) gels and compared against SCMC 30 (gel containing conventional SZ) for texture, mucoadhesion, drug release and inhibitory susceptibility of Aggregatibacter actinomycetomicans. Subsequently a 21 day single blind clinical trial comparing the efficacy of SCMC 30 NP and SCMC 30 was conducted. SCMC 30 NP showed a maximum mucoadhesion force (43.27 +/- 4.10 gf), low hardness (12.28 +/- 0.17 N), moderate gel strength (8.53 +/- 0.21 N) and elasticity (5.50 +/- 0.03 mm). 'Well' diffusion data revealed qualitatively greater antibacterial activity of SCMC 30 NP. Dissolution studies demonstrated diffusion controlled release of SZ at concentrations above MIC. SCMC 30 NP caused a significant (P < 0.05) decrease in clinical markers of periodontitis, i.e. gingival index and pocket depth as compared to SCMC 30. Also reduction in the plaque index produced by SCMC 30 NP was highly significant (P < 0.01) as compared to SCMC 30 at the end of the 21st day of clinical study. Amelioration of disease was improved due to Th-2 biased immuno shifting mediated by G-PNPs, which increased secretion of anti-inflammatory cytokines like IL-4 and TGF-beta from J774 macrophages. Clinical benefits incurred along with ease of application calls for a scaled up investigation of SCMC 30 NP.
机译：这项研究的目的是通过利用含有免疫活性神经节苷脂涂层的聚合物纳米颗粒（G-PNP）的含萨那达唑（SZ）的粘膜粘附凝胶来减轻牙周治疗中的缺陷。纳米沉淀被用来制造负载SZ的G-PNP。在我们之前的讨论中，常规SZ的水分散性提出了剂量一致性问题。 G-PNP的使用缓解了这些担忧，因为DSC和XRD数据表明，当SZ被捕获在纳米粒子的聚合物基质中时，它会变成非晶态（比晶体SZ更具水分散性）。将G-PNP添加到羧甲基纤维素钠（SCMC 30 NP）凝胶中，并与SCMC 30（包含常规SZ的凝胶）进行比较，以了解其集合体，粘膜粘附，药物释放和放线杆菌的抑制敏感性。随后进行了一项为期21天的单盲临床试验，比较了SCMC 30 NP和SCMC 30的疗效。 SCMC 30 NP表现出最大的粘膜粘附力（43.27 +/- 4.10 gf），低硬度（12.28 +/- 0.17 N），中等的凝胶强度（8.53 +/- 0.21 N）和弹性（5.50 +/- 0.03 mm）。 “很好”的扩散数据表明，SCMC 30 NP的定性抗菌活性更高。溶出度研究表明浓度高于MIC时SZ的扩散受控释放。与SCMC 30相比，SCMC 30 NP导致牙周炎的临床指标（即牙龈指数和囊袋深度）显着降低（P <0.05）。SCMC30 NP产生的牙菌斑指数降低也非常显着（P <0.01），因为在临床研究第21天结束时与SCMC 30进行了比较。由于G-PNP介导的Th-2偏向免疫转移，改善了疾病的缓解，从而增加了J774巨噬细胞的抗炎细胞因子（如IL-4和TGF-β）的分泌。伴随着临床益处以及易于使用，需要对SCMC 30 NP进行大规模研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号